J&J Medical Connect
Pulmonary Hypertension
Pulmonary Hypertension

Congress Materials – CardioVascular Clinical Trialists (CVCT 2025)

 

2025 CardioVascular Clinical Trialists | Dec 8-10 | Washington, DC

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses.  Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

 

Dose rationale for UNISUS, an ongoing, event-driven, phase III superiority study evaluating macitentan 75mg vs 10mg in pulmonary arterial hypertension (PAH)

Dénes Csonka, Gurinderpal Doad, Juan José Pérez-Ruixo


View poster

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.